JINHAI MED TECH (02225) has announced its interim results for the six-month period ending June 30, 2026, showcasing a substantial surge in financial performance.
The company recorded total revenue of S$34.021 million, representing a remarkable year-on-year increase of 134.16%.
Despite the strong top-line growth, the group reported a loss attributable to shareholders of S$4.362 million, which narrowed by 57.46% compared to the prior corresponding period.
The loss per share stood at S$0.0008, reflecting the improved earnings trajectory as the company continues to scale its operations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments